Press Releases

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO. Mr. West is a seasoned biopharma executive with over 25 years of

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into an additional services agreement to identify the efficacy of novel drug candidates in preclinical animal models of Drav

Veeva Systems today announced that Adare Pharma Solutions, a contract development and manufacturing organization specializing in oral dosage forms, has selected  Veeva Vault Quality Suite  to harmonize quality systems across the organization. By replacing legacy systems with modern connected apps, Adare can streamline quality processes, work more efficiently with partners and suppliers, and provide greater visibility into customer operations. "As Adare expands its bus

H.B. Fuller  one of the world’s leading adhesives suppliers, announces the launch of Swiftmelt 1515-I, its first bio-compatible product compliant in IMEA – India, Middle East, and Africa. The product is for medical tape applications to be used in stick-to-skin under unique climatic conditions, such as the high temperatures and humidity in the Indian sub-continent.Swiftmelt 1515-I delivers effective high tack, secure and quick bonding, under high temperature and with shear res

Avel eCare, the nation's leading provider of clinician-to-clinician telemedicine services, today announced the acquisition of NightWatch, a West Virginia-based company that provides remote pharmacy services to hospitals, clinics and nursing homes throughout the Midwest and mid-Atlantic region. The acquisition strengthens Avel's existing suite of telemedicine offerings and enables the company to expand its reach to better service customers across the United States. "We a

Innovent Biologics, Inc.a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the first participant has been successfully dosed in a multicenter, randomized, dulaglutide-controlled phase 3 clinical trial of mazdutide a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese patients with type 2 diabet

Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc.the leader in enabling the development and supply of better treatments for patients worldwide. Under the terms of the agreement, Avantor will be the primary supplier of a broad range of laboratory supplies, clinical and p

Illumina Inc. a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples. The sample cohort is primarily made up of DNA from African Americans, who are currently underrepresented in research for the clinical applications of genomics, including drug target disc

Jacobio Pharma announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S.JAB-2485 is a highly selective small molecule Aurora A inhibitor. At present, there is no commercialized Aurora A inhibitor globally. Jacobio's self-developed JAB-2485 is the third Aurora A inhibitor entered into clinical stage in the United States. This clinical trial will be complet

Helix, the leading population genomics and viral surveillance company in the nation, announced today a global strategic partnership with QIAGEN N.V. the leading global provider of Sample to Insight solutions, to jointly develop companion diagnostics for hereditary diseases. As part of the collaboration, Helix will leverage the Helix Laboratory Platform to develop companion diagnostics in the U.S., and QIAGEN will use the QIASeq Human Exome Kits in the rest of world. The Helix Labora